Cassava Sciences Inc (SAVA)
27.08
+0.12
(+0.45%)
USD |
NASDAQ |
Oct 04, 16:00
27.07
-0.01
(-0.04%)
After-Hours: 20:00
Cassava Sciences Research and Development Expense (TTM): 73.76M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 73.76M |
| March 31, 2024 | 83.54M |
| December 31, 2023 | 89.42M |
| September 30, 2023 | 88.34M |
| June 30, 2023 | 83.27M |
| March 31, 2023 | 75.25M |
| December 31, 2022 | 68.03M |
| September 30, 2022 | 60.72M |
| June 30, 2022 | 50.24M |
| March 31, 2022 | 37.19M |
| December 31, 2021 | 24.81M |
| September 30, 2021 | 15.99M |
| June 30, 2021 | 8.348M |
| March 31, 2021 | 5.038M |
| December 31, 2020 | 3.053M |
| September 30, 2020 | 2.272M |
| June 30, 2020 | 1.821M |
| March 31, 2020 | 1.538M |
| December 31, 2019 | 1.568M |
| September 30, 2019 | 0.832M |
| June 30, 2019 | 1.32M |
| March 31, 2019 | 2.475M |
| December 31, 2018 | 2.969M |
| September 30, 2018 | 4.511M |
| June 30, 2018 | 5.694M |
| Date | Value |
|---|---|
| March 31, 2018 | 7.294M |
| December 31, 2017 | 7.614M |
| September 30, 2017 | 7.405M |
| June 30, 2017 | 8.443M |
| March 31, 2017 | 6.969M |
| December 31, 2016 | 9.176M |
| September 30, 2016 | 11.46M |
| June 30, 2016 | 11.16M |
| March 31, 2016 | 11.56M |
| December 31, 2015 | 9.10M |
| September 30, 2015 | 6.588M |
| June 30, 2015 | 6.348M |
| March 31, 2015 | 6.297M |
| December 31, 2014 | 7.306M |
| September 30, 2014 | 7.349M |
| June 30, 2014 | 6.677M |
| March 31, 2014 | 5.881M |
| December 31, 2013 | 4.917M |
| September 30, 2013 | 5.867M |
| June 30, 2013 | 6.802M |
| March 31, 2013 | 7.179M |
| December 31, 2012 | 7.605M |
| September 30, 2012 | 7.215M |
| June 30, 2012 | 6.855M |
| March 31, 2012 | 7.731M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
1.538M
Minimum
Mar 2020
89.42M
Maximum
Dec 2023
40.75M
Average
37.19M
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| Bristol-Myers Squibb Co | 10.31B |
| Eli Lilly and Co | 10.21B |
| Seelos Therapeutics Inc | 20.43M |
| Biomarin Pharmaceutical Inc | 786.34M |
| EyePoint Pharmaceuticals Inc | 95.28M |